Effects of Jianpi Bushen Prescription on Hematopoiesis and Immune System in Tumor Patients After Radiotherapy
10.13422/j.cnki.syfjx.20242397
- VernacularTitle:健脾补肾方对肿瘤患者放疗后造血及免疫系统的影响
- Author:
Junyang SUN
1
;
Dongchu HE
1
Author Information
1. Hubei University of Chinese Medicine，Hubei 430065，China
- Publication Type:Journal Article
- Keywords:
tumor;
radiotherapy;
radiation injury;
Jianpi Bushen prescription;
hematopoietic function;
immune function
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(21):219-226
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the preventive and therapeutic effects of Jianpi Bushen prescription （JBP） on hematopoiesis and immune system damage in tumor patients after radiotherapy. MethodSixty-four patients diagnosed with tumors of qi and blood deficiency syndrome， who received radiotherapy for the first time at the department of oncology and radiotherapy of Central Theater General Hospital of PLA from January 2023 to December 2023， were enrolled and randomly divided into the JBP combined with radiotherapy group （observation group） and the radiotherapy alone group （control group） at a ratio of 1∶1， with 32 patients in each group. The clinical efficacy of Western medicine， traditional Chinese medicine （TCM） syndrome efficacy， TCM syndrome scores， blood routine tests， immunological indicators， cytokines， and Karnofsky Performance Status （KPS） scores were compared between the two groups before and after treatment. Adverse reactions during the treatment process were observed to assess the safety of the treatment. ResultA total of 61 patients were ultimately included in this study， with 29 patients in the observation group and 32 in the control group. Compared with pre-treatment levels， the observation group showed significant reductions in the primary and secondary symptoms of qi and blood deficiency syndrome， total symptom score， peripheral blood white blood cell count （WBC）， red blood cell count （RBC）， hemoglobin （HGB）， blood platelet （PLT）， lymphocyte （LYM）， CD3+， CD4+， CD4+/CD8+ ratio， interleukin （IL）-4， and IL-10 levels after treatment （P<0.05，P<0.01）.Meanwhile，the levels of peripheral blood CD8+，IL-6，interferon （IFN）-γ，tumor necrosis factor （TNF）-α，IL-17， and KPS scores significantly increased （P<0.05， P<0.01）. In the control group， significant reductions were also observed in the primary symptoms of qi and blood deficiency syndrome， total symptom score， peripheral blood WBC， RBC， HGB， PLT， LYM， CD3+， CD4+， CD4+/CD8+ ratio， IL-4， IL-10， and IL-17 levels （P<0.05， P<0.01）， along with significant increases in peripheral blood CD8+， IL-6， IFN-γ， TNF-α， and KPS scores （P<0.05， P<0.01）. After treatment， the total effective rate of TCM syndrome in the observation group was 86.2% （26/29）， ， higher than 50.0% （22/32） in the control group （χ2 = 16.543， P<0.01）. The total clinical remission rate in the observation group was 51.7% （15/29）， higher than 25.0% （8/32） in the control group （χ2 = 9.159， P<0.05）. Compared with the control group after treatment， the observation group had higher levels of peripheral blood WBC， RBC， HGB， PLT， LYM， CD3+， CD4+， CD4+/CD8+ ratio， IL-4， IL-10， and KPS scores （P<0.05）， and lower levels of peripheral blood CD8+， IL-6， IFN-γ， TNF-α， and IL-17 （P<0.05）. The most common adverse events in both groups were bone marrow suppression， radiation dermatitis， radiation esophagitis， nausea， and vomiting. The incidence of bone marrow suppression， nausea， and vomiting in the observation group was significantly lower than that in the control group （P<0.05）. ConclusionJBP can effectively improve the clinical efficacy in tumor patients undergoing radiotherapy， alleviate symptoms of qi and blood deficiency， slow down the reduction rate of peripheral blood WBC， RBC， HGB， PLT， and LYM levels， improve hematopoietic function， slow down the reduction rate of peripheral blood CD3+ T cells， CD4+ T cells， CD4+/CD8+ ratio， and cytokines IL-4 and IL-10， enhance the immunity of tumor patients， reduce the expression of cytokines IFN-γ， IL-6， IL-17， and TNF-α， alleviate inflammatory reactions， and reduce the occurrence of post-radiotherapy adverse reactions， thus demonstrating high clinical application value.
